Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

The FDA has agreed in court to allow compounding pharmacies to continue producing compounded versions of LLY's tirzepatide ...

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of the wildly popular drug.

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...

Eighty states, cities, counties, school boards and unions have joined litigation in a New Jersey district court against the three major pharmacy middlemen.

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it acquired Novartis' global vaccine business in 2015. Only by tapping into ...

Streeting announced a collaboration with the world's largest pharmaceutical company, Lilly, which will include a five-year ...